An antiviral drug paper published just to promote JABS!
Molnupiravir, developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP - Oct. 26, 2021. The COVID-19 antiviral drug Molnupiravir helps speed up recovery from the virus but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, a new study has found. Molnupiravir, from Ridgeback Biotherapeutics and Merck & Co. is used to treat mild to moderate COVID-19 and can be taken at home, twice a day for five days, within five days of symptoms onset. It works by stopping the virus from replicating, keeping levels low in the body, thus reducing its severity. The study was published in The Lancet on Dec. 22 and has been peer reviewed. For more tedious reading go to the source ***** This is the FUN part of the paper: In conclusion, this trial of vaccinated adults at increased risk of an adverse outcome and unwell with confirmed SARS-CoV-2 infection showed that early treatment with molnupiravir did not reduce already low